Anti-cd27 monoclonal antibody and use thereof
AssigneeShanghai Celgen Bio-Pharmaceutical Co., Ltd.
InventorsZeling CAI, Yi CHEN
Life of this patent
Estimating the term…
Abstract
The present invention provides an anti-CD27 monoclonal antibody and a preparation thereof. Particularly, the present invention provides a novel anti-CD27 antibody. The antibody of the present invention can bind to an antigen with high specificity, has high affinity and high biological activity, and can specifically bind to human CD27 antigen molecules. Therefore, the antibody is expected to be used for producing drugs capable of efficiently carrying out immunotherapy in vitro and in vivo.
Claims22
An antibody, wherein the antibody has a heavy chain comprising a heavy chain variable region and a light chain comprising a light chain variable region, wherein the heavy chain variable region has three complementarity determining regions (CDRs) selected from the group consisting of:
- (a) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 2, 3 and 4;
- (b) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 2, 25 and 4;
- (c) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 2, 26 and 4;
- (d) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 10, 11 and 12;
- and the light chain variable region has three complementarity determining regions (L-CDRs) whose sequences are shown in SEQ ID No:
- 6, 7, and 8;
- or the light chain variable region has three complementarity determining regions L-CDRs whose sequences are shown in SEQ ID No:
- 14, 15, and 16.
3-8. (canceled)
A CAR construct, wherein the scFv segment of the antigen binding region of the CAR construct is a binding region that specifically binds to CD27, and the scFv has a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region has three complementarity determining regions (CDRs) selected from the group consisting of:
- (a) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 2, 3 and 4;
- (b) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 2, 25 and 4;
- (c) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 2, 26 and 4;
- (d) CDR1, CDR2 and CDR3 shown in SEQ ID No:
- 10, 11 and 12;
- and the light chain variable region has three complementarity determining regions (L-CDRs) whose sequences are shown in SEQ ID No:
- 6, 7, and 8;
- or the light chain variable region has three complementarity determining regions L-CDRs whose sequences are shown in SEQ ID No:
- 14, 15, and 16.
(canceled)
Dependencies are inferred from the claim text.